Feb 24, 2009 | Laboratory News, Laboratory Pathology
February 24, 2009
Are you curious about how molecular imaging and molecular diagnostics are being integrated into a single clinical service? If so, you may want to go to the Siemens Corporation Web site. On the home page, it prominently features video of events at the Molecular Summit on the Integration of In Vivo and In Vitro Diagnostics, conducted in Philadelphia earlier this month!
Throughout the two-day Molecular Summit event, Siemens conducted video interviews with selected speakers. These interviews, and video of selected presentations, are easily accessible on the Siemens Web site. In fact, you can even see a video interview with Dark Daily Editor Robert Michel, who produces the Molecular Summit each year! Just hit the link with his picture .
Siemens’ interest in the Molecular Summit is directly linked to one of its primary global strategies. In recent years, Siemens placed a $14 billion bet on the integration of molecular imaging and molecular diagnostics by acquiring, in order, Diagnostic Products Corporation (DPC), Bayer Diagnostics, and Dade Behring Corporation. By 2007, Siemens had become the world’s second largest in vitro diagnostics (IVD) manufacturer, as well as the world’s largest integrated diagnostics company.
Pathologists and laboratory managers will want to pay closer attention to how radiology and pathology are evolving toward a single clinical service. This is a trend which is in its infancy. It won’t be disruptive in the short term. On the other hand, presentations at Molecular Summit by radiologists and pathologists who have begun to collaborate on an integrated clinical diagnostic service reveal that such efforts easily generate additional value to clinicians and improve outcomes for patients. Two examples of in vivo and in vitro integration can by found at the University of Kansas and at UCLA Medical Center. Pathologists and radiologists from both sites made presentations on their collaborative diagnostic services at the Molecular Summit.
Of course, the glue that will increasingly bind radiologists and pathologists together is personalized medicine. Molecular Summit speakers ranging from George Poste, DVM, PhD, to Mara Aspinall, PhD, told attendees that personalized medicine is no longer a concept, but is an active and expanding influence in healthcare today. Personalized medicine requires pathologists and radiologists to adopt molecular technologies and to evaluate disease processes at a cellular level, increasingly in a multiplex, multi-modality process.
The second annual Molecular Summit, produced by The Dark Report, was conducted in Philadelphia on February 10-11, 2009. An enthusiastic audience of almost 200 pathologists, radiologists, and other experts focused on this new vision for molecular imaging and molecular diagnostics. For two years, Siemens has been a corporate benefactor of Molecular Summit.
Dark Daily invites subscribers and readers to share their experiences at integrating imaging and molecular pathology. Planning for Molecular Summit 2010 is already under way and this is an opportunity for you to present your case study of in vivo/in vitro integration at next year’s event. Contact Editor Robert L. Michel at rmichel@darkreport.com.
Related Information:
Feb 11, 2009 | Laboratory News, Laboratory Pathology
Powerful, fast-moving trends are propelling pathology and radiology toward personalized medicine
February 11, 2009
It is no exaggeration to characterize the advances in molecular technologies as a huge “molecular asteroid” on a target path to smash Planet Pathology and Planet Radiology. That is the collective wisdom shared by experts speaking here in Philadelphia yesterday and today at the second annual Molecular Summit on In Vivo and In Vitro Integration.
This important conference, produced by The Dark Report, is the only global event which brings together innovators in the fields of molecular imaging, molecular diagnostics, and health informatics to share their progress on establishing integrated diagnostic and therapeutic services for clinicians and patients. Yesterday’s podium fireworks offered attendees impressive insights on the current level of molecular transformation underway in molecular imaging and molecular diagnostics-along with a impressive consensus on the future for these diagnostic areas.
For example, keynote speaker George Poste, DVM, Ph.D., Chief Scientist and Director of The Biodesign Institute of Arizona State University, laid out a compelling argument that personalized medicine is an unstoppable trend. Poste, a leading international expert on biomarkers, declared that multi-modality diagnostics will play an essential role in how healthcare evolves toward a pro-active healthcare system organized to serve the needs of personalized medicine.
Of particular interest to pathologists and laboratory professionals, Poste characterized the field of diagnostics as rapidly organizing around multiplex, automated, miniaturized assays, amid plenty of chaos as new science and technologies upset long-standing practices in laboratory medicine. He illustrated this chaos by noting that “there are approximately 157,000 biomarkers in the literature with some claim of validity. These biomarkers were developed mainly in academic settings and are supported mostly by anecdotal evidence.”
Throughout the day, experts at the Molecular Summit podium stressed several common themes about how molecular imaging and molecular diagnostics is transforming. These are valuable insights for the many pathologists and radiologists who work in community hospital settings and don’t often have the opportunity to participate in conferences such the Molecular Summit on In Vivo and In Vitro Integration:
* Personalized medicine is already happening. It is not an idea, but is now an active trend in the American healthcare system.
* There will be swift progress to move away from single-analyte assays (such as potassium and chloride) and single biomarker tests (such as HER2/Neu) in favor of multi-analyte assays. Microarrays with their tens of thousands of data points are just one example of how diagnostics is incorporating huge amounts of measurement points.
* Multi-modality disease assessment will become the norm. Molecular imaging, molecular diagnostics, and other relevant clinical data sets will be pulled together and assessed. Diagnosticians will then provide an integrated answer to the clinicians. This integrated answer will address diagnosis, therapeutic options, and patient monitoring.
* In anatomic pathology, technology will make it possible to extract quantitative data from specimens. The technology will reduce human variability in assessment of the specimen and will provide richer information for diagnosis, to guide therapeutic decisions, and patient monitoring.
Dark Daily will provide more insights from this Molecular Summit, which continues through the end of today. As noted above, there is strong consensus among the speakers that a transformation of diagnostic services is underway. Such a consensus among numerous experts in molecular imaging, molecular diagnostics, and health informatics is, by itself, confirmation that a major trend is unfolding.
Armed with this understanding, it explains why the metaphor of a huge molecular asteroid striking Planet Pathology and Planet Pathology is apt. Look for additional intelligence about the presentations and insights emerging from this year’s Molecular Summit!
Your Dark Daily Editor,
Robert L. Michel
Related Information:
2009 Molecular Summit on In Vivo and In Vitro Integration
